Case Report:

Fast-Tracking Variant Selection with XtenCHO® Race Small-Scale High-Throughput Production

Client

Mid-size Canadian biotech

Sector

Biotechnology

Research Domain

Oncology

Timeframe

3 weeks

Key Processes

Antibody sequence optimization & vector design
Transient expression with XtenCHO® Race & purification
Yield evaluation & variant selection

Key Numbers

7.0

mg/30mL

Maximum Yield

antibodies

Produced in High-Throughput

days

to Culture and Harvest

Context

A mid-size Canadian biotech developing a therapeutic antibody for colorectal cancer approached us to accelerate their candidate selection process. They had generated 18 antibody sequences in-house and needed a rapid way to evaluate their production yields. Instead of testing production internally, which would have cost more time and resources, they sent the sequences to us for small-scale expression and yield comparison.

Challenges

1

Time pressure to produce and test many antibody variants in parallel

2

Securing enough material for downstream tests

3

Need for consistent quality (purity >90%) across all candidates

4

Ensuring scalability from pilot to larger volumes without loss of performance

ProteoGenix Approach

Sequence optimization & vector construction
XtenCHO^® Race transient transfection (30 ml scale)
14-day culture & harvest
Protein A purification
QC via SDS-PAGE and yield calculation

Results

Using the XtenCHO® Race platform, ProteoGenix successfully produced all 18 antibody variants in parallel, achieving yields ranging from approximately 2 mg to over 7 mg per 30 mL culture with purity above 90%. Several variants demonstrated particularly promising expression levels, ensuring the client received sufficient quantities of material to continue their downstream assays. With these results, the biotech was able to confidently narrow their focus and select 8 antibodies for detailed affinity testing, effectively streamlining their development pipeline.

Key Takeway

Early yield evaluation with XtenCHO® Race enabled a rapid first selection of candidates. This allowed the client to save time and money while keeping the quality and consistency needed to confidently advance their therapeutic program with their new variants selection.